1.. Introduction   {#sec1}
==================

The aspartate receptor Tar is a transmembrane protein of 553 amino-acid residues in length consisting of a first membrane-spanning α-helix, a periplasmic domain, a second membrane-spanning α-helix and a cytoplasmic domain (Krikos *et al.*, 1983[@bb8]). Tar mediates bacterial chemotaxis towards attractants including aspartate (Asp) and maltose, and away from repellents such as nickel and cobalt ions (Reader *et al.*, 1979[@bb13]; Wang & Koshland, 1980[@bb15]). Transmembrane signalling by Tar requires a homodimeric structure of the receptor (Milligan & Koshland, 1988[@bb11]). How the attractants and repellents regulate the activity of Tar during chemotaxis is still unknown.

The first crystal structures of the Tar periplasmic domain were determined using cysteine cross-linked dimers in the absence and presence of bound aspartate in *Salmonella typhimurium* (Milburn *et al.*, 1991[@bb10]). Other crystal structures of the Tar periplasmic domain in the Asp-bound and unbound forms were subsequently reported (Bowie *et al.*, 1995[@bb2]; Chi *et al.*, 1997[@bb4]; Scott *et al.*, 1993[@bb14]; Yeh *et al.*, 1993[@bb17], 1996[@bb18]; Yu & Koshland, 2001[@bb19]). Comparison of the two structures in the absence and presence of bound aspartate demonstrated a ∼1.0 Å vertical shift of the second transmembrane α-helix relative to the first (Milburn *et al.*, 1991[@bb10]; Chervitz & Falke, 1996[@bb3]; Ottemann *et al.*, 1999[@bb12]). It has been proposed that in transmembrane signalling, Asp binding to the periplasmic domain of Tar induces a piston-like displacement of the second transmembrane α-helix (reviewed in Falke & Hazelbauer, 2001[@bb5]). While the crystal structure of the apo form of the Tar periplasmic domain has been determined (Bowie *et al.*, 1995[@bb2]; Chi *et al.*, 1997[@bb4]), there has been no report of the crystal structure of the Asp-bound form of Tar from *Escherichia coli*.

Maruyama *et al.* (1995[@bb9]) previously proposed an alternative model in which the repellents stabilize the second transmembrane α-helix in a different rotational orientation from those of the apo and Asp-bound forms through a rotation/twist of the second transmembrane α-helix parallel to the plane of the cytoplasmic membrane. The model also predicts that apo-Tar and Asp-bound Tar have similar structures. Structural analysis of the HAMP domains, which are located immediately downstream of the second transmembrane α-helix, implies domain rotation in transmembrane signalling (Hulko *et al.*, 2006[@bb6]). To test the rotation/twist model, the *E. coli* Tar periplasmic domain was crystallized with and without bound aspartate (Asp-Tar and apo-Tar, respectively). Here, the expression, purification, crystallization and preliminary X-ray diffraction studies of Asp-Tar and apo-Tar are described.

2.. Materials and methods   {#sec2}
===========================

2.1.. Cloning   {#sec2.1}
---------------

A plasmid, pET-Tar, that expresses the periplasmic domain, residues 26--193 (TAR-E), of *E. coli* Tar was constructed using the expression vector pET-28a(+) (Novagen). This construct encodes an N-terminal methionine, a six-His tag and thrombin-recognition and enterokinase-recognition sites, followed by a Tar periplasmic sequence encompassing Gly26--Gln193. A DNA fragment encoding the periplasmic domain of Tar was amplified by PCR from *E. coli* DH5α genomic DNA using the forward primer 5′-ATG **GCT AGC** GAT GAC GAC GAC AAG GGC AGC CTG TTT TTT TCT TC-3′ (*Nhe*I site in bold) and the reverse primer 5′-CTC **GAA TTC** TCA TTA TTG CCA CTG GGC AAA TC-3′ (*Eco*RI site in bold). The resulting PCR product was digested with *Nhe*I and *Eco*RI, and was cloned into pET-28a(+) using a DNA ligation kit (Takara Bio, Tokyo, Japan). This construct was termed pET-Tar.

2.2.. Expression   {#sec2.2}
------------------

An overnight culture of *E. coli* BL21 (DE3) cells (Invitrogen) harbouring pET-Tar was made by inoculating a single colony in 10 ml LB medium containing 30 µg ml^−1^ kanamycin. This overnight culture was poured into 1000 ml LB medium containing 30 µg ml^−1^ kanamycin, which was then grown at 37°C with agitation at 250 rev min^−1^ to an OD~600~ of 0.3. To this culture, isopropyl β-[d]{.smallcaps}-1-thiogalactopyranoside (IPTG; Nacalai Tesque, Kyoto, Japan) was added to a final concentration of 0.1 m*M* to induce the production of TAR-E. Cultivation was continued for an additional 4 h and cells were harvested by centrifugation at 6000*g* for 5 min.

2.3.. Purification   {#sec2.3}
--------------------

The harvested cell paste was resuspended in 10 ml suspension buffer (20 m*M* sodium phosphate buffer pH 7.4, 500 m*M* NaCl, 30 m*M* imidazole) with the addition of 100 µl protease-inhibitor cocktail (Nacalai Tesque) and was sonicated on ice for 40 min with an ultrasonic disruptor (Tomy Seiko, Tokyo, Japan). The resulting cell suspension was centrifuged at 6000*g* for 10 min at 4°C and resuspended in 10 ml resuspension buffer (8.0 *M* urea, 20 m*M* sodium phosphate pH 7.4, 500 m*M* NaCl) with the addition of a further 50 µl protease-inhibitor cocktail. A second sonication was carried out on ice for 1 min and the resulting suspension was pelleted by centrifugation at 20 000*g* for 15 min at 4°C. The resulting supernatant was cleared by filtration with a 0.45 µm HPLC filter (Pall Corp.).

From the cleared lysate, TAR-E was first purified by affinity chromatography with two tandemly connected 5 ml HisTrap FF columns (GE Healthcare). Before application of the sample, the columns were washed with three column volumes of washing buffer (8 *M* urea, 50 m*M* Tris--HCl pH 8.0, 200 m*M* NaCl). The cleared lysate was applied onto the HisTrap columns equilibrated with washing buffer at a flow rate of 1 ml min^−1^ for 40 min. Refolding of the bound TAR-E was performed by applying a linear urea gradient from 8.0 to 0.0 *M* in buffer consisting of 50 m*M* Tris--HCl pH 8.0, 200 m*M* NaCl at a flow rate of 1.0 ml min^−1^ for 60 min. Elution of refolded proteins was performed by applying a linear imidazole gradient ranging from 0 to 500 m*M* in buffer consisting of 50 m*M* Tris--HCl pH 8.0, 200 m*M* NaCl at a flow rate of 1 ml min^−1^ for 60 min. Eluted TAR-E was further purified by gel-filtration chromatography with a HiLoad column (26/600 Superdex 75 pg; GE Healthcare) equilibrated with 1.0 m*M* EDTA, 10 m*M* Tris--HCl pH 8.0, 100 m*M* NaCl by FPLC at a flow rate of 1.0 ml min^−1^. Fractions containing TAR-E, ∼30 ml, were dialyzed against buffer consisting of 0.6 *M* NaCl, 10 m*M* HEPES--NaOH pH 7.5 and were concentrated by ultrafiltration using Vivaspin 6 (Vivaproducts, Massachusetts, USA). Protein purity was assessed by SDS--PAGE (14%), followed by staining with Coomassie Brilliant Blue. Concentrated TAR-E at 11.6--15.9 mg ml^−1^ was immediately used for crystallization without freezing. During cleavage with thrombin or enterokinase in order to remove the tag, His-tagged TAR-E precipitated for unknown reason(s). Therefore, TAR-E protein was directly used for crystallization without protease digestion.

2.4.. Crystallization using ammonium sulfate as a precipitant   {#sec2.4}
---------------------------------------------------------------

All crystallization experiments were performed in 24-well VDX plates with sealant (Hampton Research, California, USA) against a 1.0 ml reservoir. Previously reported conditions for crystallization (Bowie *et al.*, 1995[@bb2]) were employed with slight modification. Crystals of apo-Tar1 were grown by mixing 1.5 µl purified TAR-E protein solution (0.6 *M* NaCl, 10 m*M* HEPES--NaOH pH 7.5, 15.9 mg ml^−1^ TAR-E) with 1.5 µl crystallization solution \[0.4 *M* ammonium sulfate, 35 m*M* ammonium formate, 15 m*M* formic acid, 1.25%(*v*/*v*) glycerol pH 3.9\] on a siliconized glass cover slide at 10°C. Hanging drops consisting of 1.5 µl each of the protein and crystallization solutions were equilibrated against a 1.0 ml reservoir of crystallization solution. A crystal of apo-Tar1 was sequentially soaked in crystallization solution supplemented with 10, 20 or 30%(*v*/*v*) glycerol and was flash-cooled in liquid nitrogen (Fig. 1[▶](#fig1){ref-type="fig"} *a*).

Prior to crystallization of Asp-Tar1, 44 µl of an aspartate solution (0.6 *M* NaCl, 10 m*M* HEPES--NaOH pH 7.5, 45 m*M* aspartate) was mixed with 156 µl purified TAR-E protein solution (0.6 *M* NaCl, 10 m*M* HEPES--NaOH pH 7.5, 11.6 mg ml^−1^ TAR-E). Asp-Tar1 crystals were grown at 10°C by mixing 1.5 µl purified TAR-E solution (0.6 *M* NaCl, 10 m*M* HEPES--NaOH pH 7.5, 9.9 m*M* aspartate, 9.1 mg ml^−1^ TAR-E) with 1.5 µl crystallization solution (0.8 *M* ammonium sulfate, 20 m*M* ammonium formate, 30 m*M* formic acid pH 3.4) on a siliconized glass cover slide with streak-seeding with previously obtained Asp-Tar1 crystals. Hanging drops consisting of 1.5 µl each of the protein and crystallization solutions were equilibrated against a 1.0 ml reservoir of crystallization solution. A crystal of Asp-Tar1 was sequentially soaked in crystallization solution supplemented with 20, 30 or 35%(*v*/*v*) glycerol and was flash-cooled in liquid nitrogen (Fig. 1[▶](#fig1){ref-type="fig"} *c*).

2.5.. Crystallization using NaCl as a precipitant   {#sec2.5}
---------------------------------------------------

For crystallization of apo-Tar2 and Asp-Tar2, NaCl was also used as a protein precipitant. Crystallization conditions with modifications have previously been reported (Chi *et al.*, 1997[@bb4]). Crystals of apo-Tar2 were grown at 10°C by mixing 1.5 µl purified TAR-E solution (0.6 *M* NaCl, 10 m*M* HEPES--NaOH pH 7.5, 13.7 mg ml^−1^ TAR-E) with 1.5 µl crystallization solution (4.3 *M* NaCl, 100 m*M* Tris--HCl pH 8.0) on a siliconized glass cover slide with streak-seeding with crystals of apo-Tar1. Hanging drops consisting of 1.5 µl each of the protein and crystallization solutions were equilibrated against a 1.0 ml reservoir of crystallization solution. A crystal of apo-Tar2 was soaked in crystallization solution supplemented with 33%(*v*/*v*) glycerol and was flash-cooled in liquid nitrogen (Fig. 1[▶](#fig1){ref-type="fig"} *b*).

Crystals of Asp-Tar2 were grown at 10°C by mixing 1.5 µl purified TAR-E solution (0.6 *M* NaCl, 10 m*M* HEPES--NaOH pH 7.5, 13.5 mg ml^−1^ TAR-E) with a 1.5 µl reservoir of crystallization solution (3.5 *M* NaCl, 100 m*M* Tris--HCl pH 8.0, 25 m*M* aspartate) on a siliconized glass cover slide with streak-seeding with crystals of apo-Tar1. Hanging drops consisting of 1.5 µl each of the protein and crystallization solutions were equilibrated against a 1.0 ml reservoir of crystallization solution. A crystal of Asp-Tar2 was sequentially soaked in a crystallization solution supplemented with 25 or 33%(*v*/*v*) glycerol and was flash-cooled in liquid nitrogen (Fig. 1[▶](#fig1){ref-type="fig"} *d*).

2.6.. X-ray diffraction data collection   {#sec2.6}
-----------------------------------------

X-ray diffraction data were collected under cryogenic conditions by flash-cooling with liquid nitrogen after stepwise transfers of all crystals into the crystallization solution supplemented with 10--35%(*v*/*v*) glycerol. Diffraction data for apo-Tar1 and Asp-Tar1 were collected using an ADSC Q270 detector on the AR-NE3A beamline and an ADSC Q315 detector on the BL5A beamline at the Photon Factory, Tsukuba, Japan, respectively. Diffraction data for apo-Tar2 and Asp-Tar2 were collected using a MAR 300HE charge-coupled device (CCD) detector on the BL44XU beamline and an ADSC Quantum315 CCD detector on the BL38B1 beamline at SPring-8, Harima, Japan, respectively. Diffraction images were processed with *iMosflm* and scaled using *SCALA* in the *CCP*4 program suite (Battye *et al.*, 2011[@bb1]; Winn *et al.*, 2011[@bb16]). The crystal data statistics are listed in Table 1[▶](#table1){ref-type="table"}.

3.. Results and discussion   {#sec3}
============================

The TAR-E expression plasmid encodes the entire periplasmic domain of Tar from Gly26 to Gln193, which is the longest of the Tar periplasmic domains that have been crystallized to date (Bowie *et al.*, 1995[@bb2]; Chi *et al.*, 1997[@bb4]; Jancarik *et al.*, 1991[@bb7]; Milburn *et al.*, 1991[@bb10]; Scott *et al.*, 1993[@bb14]; Yeh *et al.*, 1993[@bb17], 1996[@bb18]; Yu & Koshland, 2001[@bb19]). TAR-E was purified to give a single band on SDS--PAGE (Fig. 2[▶](#fig2){ref-type="fig"}). The molecular mass of denatured TAR-E was estimated to be 22 kDa, which is comparable to the calculated mass (22.3 kDa).

Asp-Tar1 and apo-Tar1 were crystallized in the presence and absence of Asp, respectively (Fig. 1[▶](#fig1){ref-type="fig"}). Based on previously reported methods (Bowie *et al.*, 1995[@bb2]), the crystallization conditions for apo-Tar1 were optimized by varying the ammonium sulfate concentration in the range 0.4--1.1 *M*, by varying the buffer pH from pH 3.6 to 3.9 and by varying the incubation temperature from 10 to 25°C. Crystal nuclei appeared in 7 d in a droplet after crystallization commenced. The best crystal diffracted to 2.10 Å resolution and adopted space group *P*4~1~2~1~2 (Fig. 3[▶](#fig3){ref-type="fig"} *a*, Table 1[▶](#table1){ref-type="table"}). For crystallization of Asp-Tar1 (Fig. 1[▶](#fig1){ref-type="fig"} *c*), the conditions were optimized by varying the ammonium sulfate concentration in the range 0.4--0.8 *M* and the buffer pH from pH 3.4 to 3.9. Crystal nuclei appeared within 2 d in a droplet. The crystal of Asp-Tar1 diffracted to 2.40 Å resolution (Fig. 3[▶](#fig3){ref-type="fig"} *c*) and adopted space group *P*4~1~2~1~2 (Table 1[▶](#table1){ref-type="table"}).

Bowie *et al.* (1995[@bb2]) reported that sulfate ions occupied aspartate-binding sites in the crystals of apo-Tar when ammonium sulfate was used as a precipitant. To overcome this problem, NaCl was used as a precipitant instead of ammonium sulfate (Figs. 1[▶](#fig1){ref-type="fig"} *b* and 1[▶](#fig1){ref-type="fig"} *d*). It took a few months to obtain crystals of apo-Tar2. On the other hand, many crystal nuclei of Asp-Tar2 appeared within 7 d in a droplet after the crystallization commenced. Crystals of apo-Tar2 and Asp-Tar2 diffracted to 1.95 and 1.58 Å resolution, respectively (Figs. 3[▶](#fig3){ref-type="fig"} *b* and 3[▶](#fig3){ref-type="fig"} *d*), and adopted space groups *P*2~1~2~1~2~1~ and *C*2, respectively (Table 1[▶](#table1){ref-type="table"}). Structure determinations of all four types of crystals (apo-Tar1, apo-Tar2, Asp-Tar1 and Asp-Tar2) are currently in progress, and we have confirmed that aspartate molecules are bound in the crystals of Asp-Tar1 and Asp-Tar2 (data not shown). Furthermore, crystallization of the periplasmic domain with bound Ni^2+^ is advancing.
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![Crystals of apo-Tar1 (*a*), apo-Tar2 (*b*), Asp-Tar1 (*c*) and Asp-Tar2 (*d*). The scale bar is 200 µm in length.](f-70-01219-fig1){#fig1}

![SDS--PAGE analysis of purified TAR-E. Lane *M* contains molecular-mass standards (labelled in kDa).](f-70-01219-fig2){#fig2}

![X-ray diffraction images from crystals of apo-Tar1 (*a*), apo-Tar2 (*b*), Asp-Tar1 (*c*) and Asp-Tar2 (*d*). Resolution circles are also shown with the corresponding values.](f-70-01219-fig3){#fig3}

###### Data-collection and processing statistics

Values in parentheses are for the outermost resolution shell.

  Data collection                                    apo-Tar1                   apo-Tar2                   Asp-Tar1                   Asp-Tar2
  -------------------------------------------------- -------------------------- -------------------------- -------------------------- --------------------------------------
  X-ray source                                       AR-NE3A PF                 BL44XU SPring-8            BL5A PF                    BL38B1 SPring-8
  Detector                                           ADSC Q270                  MAR300HE                   ADSC Q315                  ADSC Q315
  Wavelength (Å)                                     1.000                      0.900                      1.000                      1.000
  Beam size (µm)                                     200 (diameter)             30.0 (diameter)            200 (diameter)             180.0 (vertical) × 88.0 (horizontal)
  Crystal-to-detector distance (mm)                  213.6                      210.0                      249.2                      200.0
  Oscillation angle (°)                              1                          1                          1                          1
  Oscillation range (°)                              180                        180                        180                        180
  Exposure time (s)                                  2.0                        1.1                        2.0                        2.2
  Space group                                        *P*4~1~2~1~2               *P*2~1~2~1~2~1~            *P*4~1~2~1~2               *C*2
  Unit-cell parameters                                                                                                                
    *a* (Å)                                          85.07                      60.65                      84.49                      81.11
    *b* (Å)                                          85.07                      73.60                      84.4                       59.76
    *c* (Å)                                          106.69                     79.13                      105.47                     79.16
   α (°)                                             90.00                      90.00                      90.00                      90.00
   β (°)                                             90.00                      90.00                      90.00                      94.84
   γ (°)                                             90.00                      90.00                      90.00                      90.00
  Molecules in asymmetric unit                       2                          2                          4                          4
  *V* ~M~ (Å^3^ Da^−1^)                              2.17                       1.98                       2.11                       2.15
  Solvent content (%)                                43.3                       38.0                       41.9                       42.8
  Mosaicity (°)                                      0.48                       0.63                       0.94                       0.52
  Resolution range (Å)                               2.10--32.00 (2.10--2.21)   1.95--36.80 (1.95--2.06)   2.40--39.54 (2.40--2.53)   1.58--31.26 (1.58--1.67)
  Measured reflections                               291572 (46683)             191802 (27700)             194541 (27924)             173532 (26746)
  Unique reflections                                 21720 (3349)               26480 (3792)               15497 (2197)               51023 (7475)
  Completeness (%)                                   92.5 (100.0)               99.9 (100.0)               99.7 (100.0)               98.7 (99.4)
  *R* ~merge~ [†](#tfn1){ref-type="table-fn"} (%)?   0.061 (0.144)              0.080 (0.293)              0.062 (0.255)              0.145 (0.278)
  Multiplicity                                       13.4 (13.9)                7.2(7.3)                   12.6 (12.7)                3.4 (3.6)
  Mean *I*/σ(*I*)                                    32.1 (16.0)                16.7 (7.1)                 28.6 (10.2)                5.8 (3.6)

*R* ~merge~ = , where *I~i~*(*hkl*) is the observed intensity of an individual reflection and 〈*I*(*hkl*)〉 is the mean intensity of that reflection.
